|
Video: What is a Stock Split?
|
|
Immix Biopharma is a clinical-stage biopharmaceutical company engaged in the development of a class of Tissue-Specific Therapeutics (TSTx) in oncology and inflammation. Co.'s primary asset, IMX-110, is for the treatment of solid tumors. IMX-110 is a negatively-charged TSTx that simultaneously disables resistance pathways with a poly-kinase inhibitor and induces tumor cell death with an apoptosis inducer, utilizing Co.'s TME Normalization Technology, delivered deep into the tumor micro-environment (TME). Co.'s TME Normalization Technology allows its drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. According to our Immix Biopharma stock split history records, Immix Biopharma has had 0 splits. | |
|
Immix Biopharma (IMMX) has 0 splits in our Immix Biopharma stock split history database.
Looking at the Immix Biopharma stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Immix Biopharma shares, starting with a $10,000 purchase of IMMX, presented on a split-history-adjusted basis factoring in the complete Immix Biopharma stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
12/17/2021 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$4.00 |
|
End price/share: |
$2.13 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-46.75% |
|
Average Annual Total Return: |
-23.47% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$5,324.62 |
|
Years: |
2.36 |
|
|
|
|
|